16366 Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices 

Trans No. Acquiring Acquired Entities 

20070928 ......................... Aktiegolaget Volvo ............................. Ingersoll-Rand Company Limited ...... Blaw-Knox Construction Equipment 

Corporation. 

20070932 ......................... Beacon Roofing Supply, Inc .............. North Coast Commercial Roofing 

Systems, Inc.

North Coast Commercial Roofing 

Systems, Inc. 

20070940 ......................... OCM Principal Opportunities Fund 

IV, lL.P.

EXCO Resources, Inc ....................... EXCO Resources, Inc. 

20070944 ......................... OCM Opportunities Fund VII, L.P ..... EXCO Resources, Inc ....................... EXCO Resources, Inc. 

20070949 ......................... Ambassadors international, Inc ......... Carnival Corporation ......................... Windstar Sail Cruises Limited. 

20070950 ......................... AP Berry Holdings, LLC .................... Berry Plastics Group, Inc .................. Berry Plastics Group, Inc. 

20070951 ......................... Vestar Capital Partners V, L.P .......... Paul Danton (Dan) Huish .................. Huish Detergents, Inc. 

20070952 ......................... Graham Partners II, L.P .................... Berry Plastics Group, Inc .................. Berry Plastics Group, Inc. 

20070953 ......................... Apollo Investment Fund VI, L.P ........ Berry Plastics Group, Inc .................. Berry Plastics Group, Inc. 

20070954 ......................... Apollo Investment Fund V, L.P ......... Apollo Investment Fund VI, L.P ........ Berry Plastics Group, Inc. 

20070968 ......................... Iconix Brand Group, Inc .................... ROCSAN Holdings, LLC ................... ROCAWEAR LICENSING, LLC. 

20070970 ......................... John D. Baker II ................................ Holdco ............................................... Holdco. 

20070971 ......................... Monomoy Capital Partners, L.P ........ Global Home Products LLP, Chapter 

11 debtor in possession.

Anchor Hocking CG Operating Company, LLC; Anchor Hocking Operating Company, LLC, Anchor 

Hocking Operating Company LLC. 

20070974 ......................... Zurich Financial Services .................. Bristol West Holdings, Inc ................. Bristol West Holdings, Inc. 

20070975 ......................... IDB Holding Corporation Ltd ............. Susan W. Shoval ............................... Guard Financial Group, Inc. 

20070977 ......................... LPL Investment Holdings, Inc ........... Pacific Mutual Holding Company ...... Pacific Select Group LLC. 

20070982 ......................... Spire Capital Partners II, L.P ............ Professional Bull Riders, Inc ............. Professional Bull Riders, Inc. 

20070984 ......................... Marathon Special Opportunity Master 

Fund, Ltd.

SPX Corporation ............................... General Signal UK Ltd. 

20070986 ......................... CRFRC–D Holdings, Inc ................... DEG Acquisitions, LLC ...................... DEG Acquisitions, LLC. 

20070991 ......................... Ares Corporate Opportunities Fund, 

L.P.

EXCO Resources, Inc ....................... EXCO Resources, Inc. 

20070995 ......................... JLL Partners Fund, V, L.P ................ Patheon Inc ....................................... Patheon Inc. 

For Further Information Contact: 

Sandra M. Peay, Contact Representative 

or Renee Hallman, Contact 

Representative. Federal Trade 

Commission, Premerger Notification 

Office, Bureau of Competition, Room H–

303, Washington, DC 20580, (202) 326–

3100. 

By Direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 07–1646 Filed 4–3–07; 8:45 am] 

BILLING CODE 6750–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology; 

American Health Information 

Community Population Health and 

Clinical Care Connections Workgroup 

Meeting 

ACTION: Meeting cancellation. 

SUMMARY: This notice announces the 

cancellation of the 15th meeting of the 

American Health Information 

Community Population Health and 

Clinical Care Connections Workgroup 

[formerly Biosurvellance Workgroup] in 

accordance with the Federal Advisory 

Committee Act (Pub. L. 92–463, 5 

U.S.C., App.) 

CANCELED DATE/TIME: April 20, 2007, 

from 10 a.m., to 3:30 p.m. Eastern 

Daylight Time. 

ADDRESSES: Hubert H. Humphrey 

Building (200 Independence Avenue, 

SW., Washington, DC 20201), Room 

505A. Please bring photo ID for entry to 

a Federal building). 

FOR FURTHER INFORMATION CONTACT: 

http://www.hhs.gov/healthit/ahic/ 

population/. 

Dated: March 27, 2007. 

Judith Sparrow, 

Director, American Health Information 

Community, Office of Programs and 

Coordination, Office of the National 

Coordinator for Health Information 

Technology. 

[FR Doc. 07–1645 Filed 4–3–07; 8:45 am] 

BILLING CODE 4150–24–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Misconduct in Science 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that on 

March 12, 2007 the Department of 

Health and Human Services (HHS) 

Debarring Official, on behalf of the 

Secretary of HHS, issued a final notice 

of debarment based on the misconduct 

in science findings of the U.S. Public 

Health Service (PHS) in the following 

case: 

Rebecca Uzelmeier (formerly known 

as Rebecca Marcus), Michigan State 

University: Based on the report of an 

investigation by Michigan State 

University (MSU) and additional 

information obtained by the Office of 

Research Integrity (ORI) during its 

oversight review, ORI found that 

Rebecca Uzelmeier, former doctoral 

student, Department of Pharmacology 

and Toxicology, MSU, committed 

misconduct in science by intentionally 

and knowingly fabricating and falsifying 

data in research supported by National 

Institute of Environmental Health 

Sciences (NIEHS), National Institutes of 

Health (NIH), granted R01 ES02520. 

ORI issued a charge letter 

enumerating the above findings of 

misconduct in science. However, on 

October 12, 2006, Ms. Uzelmeier filed a 

request for a hearing under 42 CFR part 

93 to dispute these findings before the 

U.S. Department of Health and Human 

Services (HHS) Departmental Appeals 

Board (DAB). On October 19, 2006, ORI 

moved to dismiss Ms. Uzelmeier’s 

hearing request because it failed to 

create a genuine dispute of either 

material fact or law, as required under 

42 CFR 93.504. On March 5, 2007, the 

Administrative Law Judge (ALJ) with 

the DAB ruled in ORI’s favor and 

dismissed Ms. Uzelmeier’s hearing 

request pursuant to 42 CFR 93.504(a)(2). 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices 16367 

The ALJ found that Ms. Uzelmeier’s 

hearing request raised defenses that 

either were immaterial to the charges of 

misconduct in science or that the ALJ 

had no authority to grant Ms. 

Uzelmeier’s request for relief under Part 

93. 

Specifically, Ms. Uzelmeier 

knowingly and intentionally; 

• Fabricated and falsified data in her 

research notebook primarily by multiple 

instances of using data/results generated 

from one experiment to represent data/ 

results purportedly obtained from one 

or more entirely different experiments; 

and 

• Fabricated and falsified data in her 

thesis entitled ‘‘Characterization of the 

Molecular Mechanism(s) Underlying the 

Interaction(s) between 2,3,7,8- 

tetrachlorodibenzo-p-Dioxin Mediated 

and Interferon Gamma Mediated Signal 

Transduction,’’ including falsifying and 

fabricating autoradiographic films, 

computer image files scanned from 

those films, numerical data reduced 

from those computer files, 

documentation of those results in her 

black three-ring binder, and data in 

associated multiple figures and 

projection slides. 

Ms. Uzlmeier’s research concerned 

the interaction between the 

environmental toxin, dioxin, and a 

cytokine, interferon, on cellular 

signaling in the immune system. The 

approach was to exploit dioxin, or 

‘‘TCDD’’ (2,3,7,8-tetrachlorodibenzo-pdioxin), as a probe that suppresses the 

immune system to delineate a role for 

the aryl hydrocarbon receptor protein 

(AhR), which is a cytosolic receptor that 

can be transported to the nucleus to also 

act as a nuclear transcription factor. The 

specific aim was to determine whether 

the mechanism of action of a naturally 

occurring regulatory factor, interferon-g 

(IFN-g), to antagonize the 

immunosuppressive actions of dioxin, 

was through reduced AhR signaling. 

Ms. Uzelmeier’s actions caused the 

withdrawal of a manuscript that had 

been submitted for publication, the 

withdrawal of her mentor’s PHS grant 

application, and her dismissal from 

graduate school. 

The following administrative actions 

have been implemented for a period of 

five (5) years, beginning on March 12, 

2007: 

(1) Ms. Uzelmeier has been debarred 

from any contracting or subcontracting 

with any agency of the United States 

Government and from eligibility or 

involvement in nonprocurement 

programs of the United States 

Government referred to as ‘‘covered 

transactions’’ as defined in the 

debarment regulations at 2 CFR 180 and 

376; and 

(2) Ms. Uzelmeier is prohibited from 

serving in any advisory capacity to PHS 

including but not limited to service on 

any PHS advisory committee, board, 

and/or peer review committee, or as 

consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8800. 

Chris B. Pascal, 

Director, Office of Research Integrity. 

[FR Doc. 07–1616 Filed 4–3–07; 8:45 am] 

BILLING CODE 4160–17–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Solicitation for Nominations for 

Members of the U.S. Preventive 

Services Task Force 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Solicits nominations for new 

members. 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) invites 

nominations of individuals qualified to 

serve as members of the U.S. Preventive 

Services Task Force (the Task Force). 

The Task Force, a standing, 

independent panel of private-sector 

experts in prevention and primary care, 

is composed of members appointed to 

serve for four-year terms with an option 

for reappointment. New members are 

selected each year to replace 

(approximately) one fourth of the Task 

Force members, i.e., those who are 

completing their appointments. 

Individuals nominated but not 

appointed in previous years, as well as 

those newly nominated, are considered 

in the annual selection process. 

Task Force members meet three times 

a year for two days in the Washington, 

DC area. Member duties include 

reviewing and preparing comments (off 

site) on systematic evidence reviews 

prior to discussing and making 

recommendations on preventive 

services, drafting final recommendation 

documents, and participating in 

workgroups on specific topics or 

methods. AHRQ particularly encourages 

nominations of women, members of 

minority populations, and persons with 

disabilities. Interested individuals can 

self nominate. Organizations and 

individuals may nominate one or more 

persons qualified for membership on the 

Task Force. 

Qualification Requirements: The 

mission of the Task Force is to produce 

evidence-based recommendations on 

the appropriate screening, counseling, 

and provision of preventive medication 

for asymptomatic patients seen in the 

primary care setting. Therefore, in order 

to qualify for the Task Force, an 

applicant or nominee MUST 

demonstrate the following: 

1. Knowledge and experience in the 

critical evaluation of research published 

in peer reviewed literature and in the 

methods of evidence review; 

2. Understanding and experience in 

the application of synthesized evidence 

to clinical decision-making and/or 

policy; 

3. Expertise in disease prevention and 

health promotion; 

4. Ability to work collaboratively with 

peers; and, 

5. Clinical expertise in the primary 

health care of children and/or adults, 

and/or expertise in counseling and 

behavioral interventions for primary 

care patients. Some Task Force members 

without primary health care clinical 

experience may be selected based on 

their expertise in methodological issues 

such as medical decision making, 

clinical epidemiology, behavioral 

medicine, and health economics. 

Strongest consideration will be given 

to individuals who are recognized 

nationally or intentionally for scientific 

leadership within their field of 

expertise. Applicants must have no 

substantial conflicts of interest that 

would impair the scientific integrity of 

the work of the Task Force including 

financial, intellectual, or other conflicts. 

DATES: All nominations submitted in 

writing or electronically, and received 

by Thursday, May 31, 2007, will be 

considered for appointment to the Task 

Force. 

Nominated individuals will be 

selected for the Task Force on the basis 

of their qualifications (in particular, 

those that address the required 

qualifications, outlined above) and the 

current expertise needs of the Task 

Force. It is anticipated that 4 

individuals will be invited to serve on 

the Task Force beginning in January, 

2008. AHRQ will retain and consider for 

future vacancies the nominations of 

those not selected during this cycle. 

ADDRESSES: Submit your responses 

either in writing or electronically to: 

Gloria Washington, ATTN: USPSTF 

Nominations, Center for Primary Care, 

Prevention, and Clinical Partnerships, 

Agency for Healthcare Research and 

Quality, 540 Gaither Road, Rockville, 


jlentini on PROD1PC65 with NOTICES